ABSTRACT: The use of alternative specimens in the field of toxicology was first described in 1979, when hair analysis was used to document chronic drug exposure. Since then, the use of these 'alternative' samples has gained tremendous importance in forensic toxicology, as well as in clinic toxicology, doping control and workplace drug testing. It is not surprising, therefore, that a large number of papers dealing with the determination of several classes of drugs in saliva, sweat, meconium and hair have been published ever since, owing to the fact that chromatographic equipment is becoming more and more sensitive, mass spectrometry (and tandem mass spectrometry) being the most widely used analytical tool, combined with gas or liquid chromatography. 'Alternative' specimens present a number of advantages over the 'traditional' samples normally used in toxicology (e.g. blood, urine and tissues), namely the fact that their collection is not invasive, their adulteration is difficult, and they may allow increased windows of detection for certain drugs. The main disadvantage of this kind of samples is that drugs are present in very low concentrations, and therefore high-sensitivity techniques are required to accomplish the analysis. This paper reviews a series of publications on the use of alternative specimens, with special focus on the main analytical and chromatographic problems that these samples present, as well on their advantages and disadvantages over traditional samples in documenting drug exposure.
INTRODUCTION
In the last decade, alternative or unconventional matrices have becoming more important in the field of toxicology, owing to the advantages that these specimens present when compared with 'conventional' samples used in laboratorial routine analysis. In general these samples present the advantage that collection is almost non-invasive and easy to perform. On the other hand, collection can also be achieved under close supervision, which prevents sample adulteration or substitution. Furthermore, some of these samples present larger detection windows, and therefore their range of analytical applications can be very wide.
Recent advances in analytical techniques have enabled the detection of drugs and metabolites at very low concentrations that were unthinkable a few years ago. In fact, LC/MS and LC/MS/MS techniques are increasing in popularity as confirmation techniques because of high sensitivity and specificity, and the ability to handle complex matrices. Also, LC/MS techniques do not require the time-consuming derivatization steps needed in GC/MS for a large number of compounds; however, ion suppression or enhancement due to complex matrices is a frequent analytical complication and must be addressed during method development and validation.
In fact, despite the analytical problems that liquid chromatography-based techniques can present, these are the state of art concerning analysis of alternative specimens because of their higher sensitivity, which is crucial if one takes into account the low amount of sample usually available in these situations.
Therefore, very low amounts of drugs of abuse or prescription drugs can be detected, for instance in the low picogram range for carboxy-THC, which is definite proof of cannabis consumption, using hair analysis, and for benzodiazepines, a single exposure to which in a drugfacilitated assault can be detected through hair analysis.
The first unconventional sample used was hair in the 1960s and 1970s to evaluate human exposure to toxic heavy metals, namely arsenic, lead and mercury (Hammer et al., 1971; Kopito et al., 1967) . Since then, numerous papers dealing with the determination of various classes of compounds have been published in the scientific literature, normally concerning drugs of abuse and therapy. Nowadays other alternative samples such as oral fluid, meconium or sweat are being introduced and present a wide range of applications, e.g. in therapeutic drug monitoring, workplace drug testing and prenatal exposure to drugs of abuse.
This review will deal with the most used unconventional samples, with special focus on their advantages and disadvantages, collection procedures, classes of drugs that are analyzed and analytical methods.
Hair
Hair is a product of differentiated organs in the skin of mammals. It is constituted by proteins, mainly keratin (65 -95%), water (15 -35%), lipids (1-9%) and minerals (0.25 -0.95%; Harkley and Henderson, 1989) . A rich capillary system, which provides the growing hair with the necessary metabolic material, surrounds the hair follicle (Pragst and Balikova, 2006) . It is estimated that the total number of hair follicles in adults is approximately 5 million. Hair grows at a rate of 0.6-1.4 cm per month, depending on the type of hair and anatomical site (Saitoh et al., 1969) .
The hair growth cycle is divided into the anagen (active growing), catagen (transition) and telogen (resting) stages. The proportions of anagen/telogen hair vary with anatomical site and this feature, together with variable growth rate, accounts for the observed differences in drug concentrations in hair collected from different regions. In fact, not only scalp hair can be used for analysis, and pubic hair, arm or leg hair and axillary hair have been suggested as alternative sources for drug detection when scalp hair is not available. However, care should be taken when interpreting the concentrations of drugs in these specimens, since various studies have found differences between pubic or axillary hair and scalp hair (Balabanova and Wolf, 1989; Offidani et al., 1993; Han et al., 2005) . Indeed, the latter two studies have compared methadone and methamphetamine concentrations in hair from different anatomical sites, concluding that the highest values were found in axillary hair, followed by pubic hair and scalp hair. In contrast, in another study the highest morphine concentrations were found in pubic hair, followed by head hair and axillary hair (Mangin and Kintz, 1993) . The significant differences of the drug concentrations in these studies can be explained not only by the totally different anagen/telogen ratio or growth rate, but also by a better blood circulation and a greater number of apocrine glands (Pragst et al., 1998) .
Beard hair is also a suitable specimen for analysis. This type of hair grows at about 0.27 mm per day, and therefore can be collected on a daily basis with an electric shaver.
Hair analysis is only useful if the measured drugs are a result of ingestion, rather than from other sources. Therefore, the mechanisms of incorporation of the drugs into the hair shaft must be addressed. It is generally accepted that drugs can enter the hair from three sources: (1) from the bloodstream during hair growth; (2) following excretion by sweat and sebum bathing the hair, usually after the hair emerges from the skin, and (3) from passive exposure from the hair to the drug, e.g. from smoke or dirty hands, followed by dissolution of the drug into the drug-free sweat. It is virtually impossible to distinguish between the presence of drugs derived from these two latter mechanisms and that proceeding from actual consumption, which is explained by the fact that the drugs are in an aqueous moiety, enhancing their incorporation. This is the reason why environmental exposure is sometimes called the 'stumbling block of hair testing' (Kidwell and Blank, 1996) .
Incorporation of drugs is affected by the melanin content of the hair and by the substances' lipophilicity and basicity. For instance, the effect of melanin content of the hair on drug incorporation can be studied in individuals with gray hair, showing that the concentration of basic drugs in pigmented hair can be about 10-fold higher than in non-pigmented hair (Pragst and Balikova, 2006) . In fact, it has been suggested that drugs bind to melanin, which explains the higher concentrations normally found in darker hair (Rollins et al., 2003; Mieczkowski and Kruger, 2007) .
Hair samples are best collected from the back of the head, the so-called vertex posterior. In fact, this is the region where hair grows with more homogeny, and also where the anagen/telogen ratio is higher, meaning that the number of hairs in active growth is larger. Hair should be cut as close as possible to the scalp with the aid of scissors, and the proximal zone (i.e. the zone which is closer to the root) should be clearly indicated if segmental analysis is to be performed. The sample can then be stored light and moisture protected at room temperature, for instance wrapped in aluminum foil.
Drugs are usually stable in regularly treated hair (without using aggressive cosmetic agents, such as oxidant dyes, bleaching or permanent wave), which makes them detectable for at least one year after intake (Pragst and Balikova, 2006) .
Hair is usually exposed to several agents that may impair drug testing, such as shampoos, dust, sunlight and rain. In fact, there are several studies on the effect of cosmetic treatments on drug stability in hair. For example, Martins et al. (2007) have found that the concentrations of amphetamine-type stimulants decreased in bleached hair when compared with non-bleached hair, without influencing their enantiomeric ratios. Likewise, it has been shown that this treatment affects the stability and decreases hair concentrations of other drugs (Pötsch and Skoop, 1996; Yegles et al., 2000) . Cosmetic treatments can also produce analytical interferences that may hinder the detection of drugs. This is the case for minoxidil, whose TMS derivative prevents the detection of cocaine and metabolites (Zucchela et al., 2007) .
As stated above, one of the most important pitfalls in hair analysis is environmental contamination. Indeed, if adequate measures are not taken, the risk of reporting false positive results increases, which is unacceptable, especially if there are legal implications of drug consumption. Therefore, to minimize this effect it is strongly recommended that hair analysis procedures include a washing step. Several decontamination procedures are described in the literature, and these include organic solvents, aqueous buffers, water, soaps and combinations of these Eser et al., 1997; Girod and Staub, 2000; Skender et al., 2002; Schaffer et al., 2002; Villamor et al., 2005) . There is no general consensus regarding decontamination procedures, and it is assumed that the total elimination of deposited drug is not achieved even after laborious washing procedures. Several researchers propose criteria for differentiation between drug use and environmental contamination, namely the establishment of a concentration ratio between the last wash and the hair sample Tsanaclis and Wicks, 2007a) .
Hair decontamination prior to analysis is not the only way to deal with environmental exposure. Therefore, the Society of Hair Testing also recommends the detection of drug metabolites and the use of metabolite to parent drug ratios to report positive results (Society of Hair Testing, 2004) . In fact, as environmental contamination is not totally removed even using laborious washing techniques, only the detection of drug metabolites, i.e. proceeding from endogenous metabolism, guarantees that the drug that is being measured has been actively consumed. This is of particular importance in the case of drugs that are likely to be in the environment because of the way they are consumed, such as cannabis (THC-COOH should be detected) and cocaine (where at least one metabolite should be detected, with a concentration ratio to the parent drug of higher than 0.05).
The major practical advantage of hair testing compared with urine or blood testing for drugs is that it has a larger detection window (weeks to months, depending on the length of the hair shaft, against 2-4 days for most drugs). However, it is not advisable to rely only on hair analysis, since there are issues where it cannot provide adequate results, such as short-term information on an individual's drug use, for which blood and/or urine are better specimens. On the other hand, long-term histories are only accessible through hair analysis. Therefore, one can say that these tests complement each other.
The assessment of this 'chronic exposure' to drugs is achieved by segmental hair analysis. In fact, hair grows at approximately 1 cm per month, and it is possible to associate the drug distribution pattern in the analyzed segments with a period in the past, taking into account both variable hair growth rates and intra-and interindividual differences. Furthermore, drugs are very stable within the hair matrix for long periods of time, providing that specimens are stored light-and moistureprotected. Another advantage of hair analysis when compared with blood or urine analysis is the collection procedure, because: (1) it is non-invasive and easy to perform; (2) the sample is not easy to adulterate by diluting with water (as can occur in urinalysis); and (3) in the case that there is a claim (sample switching, break in the chain of custody, etc.), it is possible to get an identical sample from the subject. Obviously, this latter is of great importance in the field of forensic toxicology.
However, hair analysis has several drawbacks, which sometimes are very difficult to handle in manageable proportions. The main problem in this type of analysis is the possibility of reporting false positive results due to environmental contamination of the hair, which can occur at any level. The fact that a drug is detected in a hair specimen does not necessarily mean that it was actively consumed. Therefore, hair specimens should be decontaminated prior to analysis, and specific metabolites of the drugs must be searched for. This may present a problem, because normally the metabolites are more polar drugs, and have less affinity for hair matrix constituents. This is the case, for example, for THC-COOH, the metabolite of THC (cannabis main constituent), which is found in hair in extremely low concentrations, usually in the low picogram range. To detect these low concentrations, mass spectrometric techniques are mandatory, using either gas or liquid chromatography.
In addition, as hair is quite a 'dirty' matrix, its constituents may interfere with chromatographic analysis, and therefore a sample cleanup step is normally required. In the development of new methods for drug detection in hair, special attention should be paid to the matrix effect, especially using liquid chromatographic methods, because they are more sensitive to ion suppression/enhancement effects.
Since the first report in the 1970s, hair analysis has aided toxicologists in several fields, such as in history and archaeology (Nakahara et al., 1997; Báez et al., 2000) , in assessing consumption profiles of drugs and alcohol by the general (Jurado et al., 1996; Hartwig et al., 2003; Tsanaclis and Wicks, 2007b) or student populations (Kidwell et al., 1997; Quintela et al., 2000) , driving licence renewals (Ricossa et al., 2000) , assessing intrauterine drug exposure (Chiarotti et al., 1996; Ursitti et al., 1997; Koren et al., 2002; Garcia-Bournissen et al., 2007) , evaluating of compliance with drug substitution therapy (Moeller et al., 1993; Kintz et al., 1998; Lucas et al., 2000; Sabzevari et al., 2004) , in the workplace and preemployment (Cairns et al., 2004) and in post-mortem toxicology . Another important application of hair analysis is in drug-facilitated crimes, in which the analytes must be detected after a single exposure, which is achieved due to the high sensitivity of LC/MS/ MS (Negrusz and Gaensslen, 2003; .
Several classes of drugs can be detected in hair, such as biomarkers of alcohol consumption, cocaine and metabolites, opiates, cannabinoids, amphetamines and other designer drugs, GHB, benzodiazepines and hypnotics, antipsychotics, antidepressants, steroids, anaesthetics, antiparkinsonics and alkaloids (Table 1) .
Hair analysis usually begins with a general screening by immunoassays, followed by a confirmation using chromatographic techniques. Gas chromatography coupled to mass spectrometry is by far the most widely used analytical tool for drug determination in hair specimens. Nevertheless, liquid chromatography-mass spectrometry (or tandem mass spectrometry) based methods are becoming more and more important in this field, owing to their better sensitivity for termolabile compounds, yielding lower limits of detection and quantitation, and the fact that time-consuming derivatization steps are not necessary to accomplish the analysis. However, before chromatographic analysis, the analytes must be (1) extracted from within the matrix (where they are bound to hair constituents) and (2) concentrated in a solvent which is compatible with the analytical instruments. There is no universal method to extract the analytes from the hair matrix, and it depends on the nature and chemical stability of the particular compound. Therefore, opioids and cocaine are best extracted using mild acidic hydrolysis (e.g. 0.05 -0.5 M hydrochloric acid), to avoid conversion of heroin or 6-acetylmorphine to morphine and of cocaine to benzoylecgonine (Girod and Staub, 2000; Romano et al., 2003; Cognard et al., 2005; Cordero et al., 2007; Tsanaclis and Wicks, 2007a) . On the other hand, stable compounds like cannabinoids and amphetamines can be extracted using strong alkaline conditions (e.g. 1 M sodium hydroxide; Quintela et al., 2000; Stanaszek and Piekoszewski, 2004; Villamor et al., 2005; Martins et al., 2005 Martins et al., , 2006 Tsanaclis and Wicks, 2007a) . Other extraction methods include buffer or solvent extraction (with, or without sonication; Paterson et al., 2001; Scheidweiler and Huestis, 2004) and enzymatic hydrolysis (Vincent et al. 1999; Quintela et al., 2000; Míguez-Framil et al., 2007) .
Following this extraction step, which is normally the most time-consuming step in hair analysis, a sample cleanup step is often required, to minimize any interference caused by endogenous compounds, which is particularly important in the case of liquid chromatographybased methods because of ion suppression/enhancement effects. This sample cleanup procedure is usually performed using liquid-liquid extraction (Sachs and Dressler, 2000; Stanaszek and Piekoszewski, 2004; Villamor et al., 2005; Nakamura et al., 2007) or solid-phase extraction (Girod and Staub, 2000; Scheidweiler and Huestis, 2004; Cognard et al., 2005; Martins et al., 2006; Moore et al., 2006a,b; Lachenmeier et al., 2006; Cordero and Paterson, 2007) . However, solid-phase microextraction (Sporkert and Pragst, 2000; Lucas et al., 2000; Musshoff et al., 2002; Nadulski and Pragst, 2007) , solidphase dynamic extraction and supercritical fluid extraction Allen and Oliver, 2000; Brewer et al., 2001 ) have also been described.
Saliva/oral fluid
Saliva is the excretion product originated from three pairs of major salivary glands (parotid, submandibular and sublingual), a great number of minor salivary glands, the oral mucosa and gingival crevices. As this excretion product is actually a fluid mixture, the term 'oral fluid' seems more appropriate to designate it, instead of 'saliva' or 'whole saliva' (Malamud, 1993) . Water (99%) is the major oral fluid constituent, and other components such as proteins (mucins and digestion enzymes) and mineral salts are also present. Its pH is 6.8 in resting situations, but an increase in the salivary flow turns it more basic (approaching the plasma's pH) as a result of higher osmolarity (Kintz and Samyn, 2000) . All these characteristics are influenced by a variety of factors, as the circadian rhythm, the type of the salivation stimulus, hormonal changes, stress, and therapeutic drugs (Aps and Martens, 2005) . The total volume of oral fluid produced by an adult may be 1000 mL/day with typical flows of 0.05 mL/min while sleeping, 0.5 mL/min while spitting and 1-3 mL/min or more while chewing (Crouch, 2005) .
Different mechanisms of drug transport are thought to occur, such as passive diffusion through the membrane, active processes against a concentration gradient, filtration through pores in the membrane and pinocytosis (Spihler, 2004) . Most of the drugs enter oral fluid by a mechanism of passive diffusion, which is dependent on the particular physicochemical properties of the compound or class of compounds, such as molecular weight (a molecular weight of less than 500 Da favors diffusion), liposolubility, pH and pK a , protein binding and ionization state (Paxton, 1979; Aps and Martens, 2005) . Therefore, the concentrations of drugs in oral fluid represent the free non-ionized fraction in the blood plasma. In fact, the fraction of drug bound to saliva and plasma protein as a function of pK a and pH can be predicted by the Henderson-Hasselbach equation (Spihler, 2004) .
A variety of methods are available for oral fluid collection (Navazesh, 1993) , including spitting, draining, (Mucklow et al., 1978) . Chewing paraffin wax, Parafilm, teflon, rubber bands, gum base and chewing gum are usually referred to as mechanical methods of stimulating saliva production. Likewise, a lemon juice drop or citric acid can be placed in the mouth to provide a gustatory stimulus for saliva production (Crouch et al., 2004) . However, the stimulation of saliva production may present several problems which can compromise drug-testing accuracy. For instance, some drugs and/or metabolites have been shown to be absorbed by Parafilm, and citric acid stimulation changes saliva pH and may alter drug concentrations. On the other hand, citric acid and cotton have also been shown to alter immunoassay drug test results (Crouch, 2005) .
CSEI-Sweep-MEKC and LC-MS LC-MS/MS GC/MS and LC/MS GC/MS/MS GC/MS LC-MS/MS LC-MS/MS LC-MS/MS LC-MS/MS LC-MS/MS LC-MS/MS ELISA/ LC/MS/MS MISPE and LC/MS/MS GC/MS GC-MS
A variety of commercial collection devices that promote easy, quick and reproducible collection are available. In general, these devices consist of a sorbent material that becomes saturated in the mouth of the donor, and after removal the oral fluid is recovered by applying pressure or by centrifugation. Spihler, 2004; Samyn et al., 2007) . Care should be taken when using these collection devices, because deficient recovery of drugs from oral fluid in the absorbent and adsorption of the drug on device components are likely to occur (Lenander-Lumikari et al., 1995; O'Neal et al., 2000; Samyn et al., 2007) .
One of the advantages of saliva testing is that the sample is collected under direct supervision without loss of privacy. In consequence, the risk of an invalid specimen being provided or sample adulteration and/or substitution (which are likely to occur in urine analysis) is reduced. In addition, monitoring of oral fluid may be especially advantageous and important when multiple serial samples are needed or when drug concentrations in children are required (Kim et al., 2002) . Other advantages are that, in principle, saliva drug concentrations can be related to plasma free-drug concentrations and to the pharmacological effects of drugs.
On the other hand, drugs that are ingested orally as well as those that can be smoked may be detected in high concentrations in oral fluid following recent use, due to residual amounts of drug remaining in the oral cavity. Therefore, and for these substances, results may not be accurate because the drug concentration found in the oral fluid may not reflect the blood-drug concentration.
Another disadvantage of studying oral fluid is that people are sometimes unable to produce sufficient amounts of material for analysis. Moreover, an important feature of urine testing is the accuracy of the on-site tests to detect drugs of abuse in fresh samples. Unfortunately, this is not the current situation for oral fluid testing (Grönholm and Lillsunde, 2001; Kintz et al., 2005a) . In addition, oral fluid contains several macromolecules (mucopolysaccharides and mucoproteins), which make it less easily pipetted than for instance urine, and may not be available from all individuals at all times, since there are drugs that can inhibit saliva secretion and cause dry mouth. Furthermore, and because drug concentration on this sample depends on plasma drug concentrations, drugs that have a short plasma half-life and are cleared rapidly from the body are detectable in saliva for a short time only, which represents a potential disadvantage over hair, sweat or urine. In fact, saliva and blood have the shortest detection windows (Spihler, 2004) .
Because of the above-mentioned advantages, oral fluid testing is an analytical tool used in therapeutic drug monitoring of various drugs (Horning et al. 1977; Bennett et al., 2003; Quintela et al. 2005; Dams et al., 2007) , pharmacokinetic studies Huestis and Cone, 2004; Drummer, 2005; Kauert et al., 2007) , and detection of illicit drugs in impaired driving (Samyn et al., 2002b; Kintz et al., 2005a; Toennes et al., 2005; Wylie et al., 2005a,b; Laloup et al., 2006; Concheiro et al., 2007; Drummer et al., 2007; Pehrsson et al., 2007) .
There is no doubt that one of the most impacting applications of oral fluid testing is in the assessment of drug-impaired driving, enabled not only by the development of several on-site collection devices, but also its easy and non-invasive sample collection procedure. In addition, the premise of a good correlation between oral fluid levels and blood levels means that oral fluid levels may be used to assess the degree of impairment of a driver.
Drugs of abuse are by far the most frequently detected substances in oral fluid specimens, because of their implications in workplace medicine and motor vehicle driving. Therefore, methods are described to detect opiates, cannabinoids, amphetamines, cocaine, benzodiazepines and other substances such as ketamine, GHB, antibiotics, analgesics, cyanides and other tobacco compounds, and sildenafil (Table 2) .
One issue that is gaining popularity within law enforcement and traffic regulation agencies is that the initial testing of oral fluid for drugs can be made in the field, by means of on-site collecting devices. Several devices are commercially available for this purpose, including instruments that provide an electronic readout (e.g. Dräger DrugTest ® and Orasure Uplink ® , Cozart Rapiscan ® and Drugread ® hand photometer) and LOD; LOQ 10 ng/mL -2 ng/mL; 2 ng/mL for MOR and COD 2 ng/mL; 3 ng/mL for MAM, hydromorphone and oxycodone 3 ng/mL; 10 ng/mL for hydrocodone 1.07 ng/mL; 5.5 ng/mL for MDA 0.71 ng/mL; 8.5 ng/mL for MDMA 0.22-1.07 ng/mL; 2 ng/mL for other compounds 5 ng/mL; 5 ng/mL for all compounds 0.7 ng/mL; 2.3 ng/mL for COD, 2.0 ng/mL; 6.7 ng/mL for MOR, 0.6 ng/mL; 2 ng/mL for MAM 1 μg/mL; 2 μg/mL for MAM, COD and acetylcodeine 2 μg/mL; 6 μg/mL for MOR 6 μg/mL; 10 μg/mL for heroin 0.37 ng/mL with Inmunoassay 0.2 mL with GC/MS/MS 2 ng/mL; 2 ng/mL 0.5-0.1 ng/mL 4 ng/mL for ELISA 2 pg/mL for GC/MS 10 pg/mL; 10 pg/mL 0.5 ng/mL for THC and CBN 1 ng/mL for CBD and 2-carboxy-tetrahydrocannabinol 0.05 ng/mL; 0.1 ng/mL for THC 0.2 ng/mL; 0.5 ng/mL for THC-COOH 1-5 ng/mL 0.5 μg/mL for AP 2 ng/mL; 10 ng/mL for all compounds 2.5 ng/mL; 5 ng/mL for AP, MDA, MDMA, MDEA 1 ng/mL; 5 ng/mL for MA 5 ng/mL; 25 ng/mL for HMA 2.5 ng/mL; 25 ng/mL HMMA 50 ng/mL; 2.5 ng/mL for MA 2.5 ng/mL for AP 5 ng/mL for MDA 25 ng/mL for the other compounds 2 ng/mL; 5 ng/mL for AP, 1 ng/mL; 2 ng/mL for MA, 5 ng/mL; 5 ng/mL for MDA, 1 ng/mL; 5 ng/mL for MDMA, 2 ng/mL; 5 ng/mL for MDEA, and 1 ng/mL; 5 ng/mL for MBDB 25 μg/L with inmunoassay -1 μg/L; 10 μg/L for all compounds 1 ng/mL; 8 ng/mL 0.5 μg/mL; 10 μg/mL for flunitrazepam 10 μg/mL; 15 μg/mL for 7-aminoflunitrazepam 0.05 ng/mL; 1 ng/mL 0. 2.7 ng/mL for OH-Ethylflurazepam, 0.3 ng/mL; 1.2 ng/mL for lorazepam, 0.4 ng/mL; 1.3 ng/mL for lormetazepam, 2.1 ng/mL; 6.9 ng/mL for diazepam, 3.0 ng/mL; 10.0 ng/mL for zolpidem, 3.9 ng/mL; 13.0 ng/mL for zopiclone, 0.0 ng/mL; 0.1 ng/mL for nitazepam 0.025 ng/mL; 0.05 ng/mL 0.20 ng/mL for temazepam and tetrazepam, 0.05 ng/mL for oxazepam, nordiazepam and diazepam 0.02 ng/mL; 0.1 ng/mL for flunitrazepam and alprazolam 0.05 ng/mL; 0.1 ng/mL for oxazepam, diazepam, lorazepam, desalkylflurazepam, clonazepam, temazepam, hydroxyethylflurazepam and nordiazepam. 0.5 ng/mL; 1 ng/mL for 7-aminoclonazepam and chlordiazepoxide 0.2 ng/mL; 0.5 ng/mL for OH-alprazolam 0.1 ng/mL; 0.5 ng/mL for 7-aminoflunitrazepam , SalivaScreen™). The main advantage of these devices is that they provide a preliminary drug result within minutes without the need for sophisticated laboratory screening equipment. However, at the moment there is no objective way to assess its performance, because there is a lack of consistency in their specifications. For example, for some of them, cut-off concentrations are used to define their detectability, whereas for others concentrations are given when drugs can be detected (Drummer, 2006) . The apparent sensitivity is often not defined in terms of consistency of detection in oral fluid specimens.
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Taking these facts into account, the results provided by these devices must be confirmed in the laboratory. Laboratorial techniques include screening procedures by ELISA-based immunoassays, which in general are adequate for opioids Kacinko et al., 2004; Lachenmeier et al., 2006) , methadone (Cooper et al., 2005b) , cocaine (Kolbrich et al., 2003; Kim et al., 2003; Cooper et al., 2004; Lachenmeier et al., 2006) , amphetamines Laloup et al., 2005c; Cooper et al., 2006) , and buprenorphine and provide a reliable means to screen oral fluid. Cannabis can be more difficult, particularly if the immunoassay has little cross-reactivity to THC. Nevertheless enzyme immunoassay has been successfully used for this drug (Niedbala et al., 2001; Moore et al. 2006c) . The same applies for benzodiazepines despite their low concentrations in oral fluid Smink et al., 2006) .
Concerning sample preparation techniques, analytes can be extracted by liquid-liquid extraction (Campora et al., 2006; Quintela et al., 2007; Pujadas et al., 2007) , solid-phase extraction with different types of extraction cartridges (Mortier et al., 2002; Jones et al., 2002; Wood et al., 2005; Ngwa et al., 2007) , or even solid-phase microextraction (Pragst, 2007) .
The introduction of LC-MS as a routine laboratory technique has enabled the benefits of high-performance liquid chromatography (HPLC) separation techniques to be linked to the high sensitivity and specificity of MS (Drummer, 2006) , which has assisted in the development of drug testing in oral fluid due to the relatively small sample volumes that can be obtained. In fact, concerning oral fluid analysis, sample volume may present a serious problem if several analyses are to be performed.
Mass-spectrometry-based methods have been also used to screen for a range of drugs (Allen et al., 2005) , some allowing the quantitation of several drugs (Gunnar et al., 2005; Campora et al., 2006; Scheidweiler and Huestis, 2006; Peters et al., 2007; Concheiro et al., 2007; Cone et al., 2007) . By the use of GC-MS or LC-MS including tandem mass spectrometry (MS-MS), low analytical limits can be achieved, even using sample volumes as low as 0.1 mL.
The main analytical problem in oral fluid testing is due to the nature of the sampling devices. Indeed, these systems contain several stabilizers and preservatives that are able to impair precise and accurate analyses. This issue is of particular importance when LC-MS/ MS is used, as ion suppression or enhancement effects are usually observed. Therefore, care must be taken when developing new analytical procedures and the possibility that these effects affect the precision and accuracy of the assay must be documented. Several papers addressing this issue have been published (Dams et al., 2003; Annesley, 2003) .
Another point of concern in oral fluid testing is drug recovery from the collection device, which may have an undesirable effect on the accuracy of the assay. In fact, if the analytes are not fully recovered from the device, the drugs' concentration on the sample may be underestimated, with consequences for their oral fluid to plasma ratio.
There have been published some recovery studies using several collection devices, suggesting that desorption of drugs may limit the usefulness of some materials. For instance, Salivette ® has poor recovery for THC but is reasonable for codeine, whereas the Cozart ® collector has good recovery for THC (Drummer, 2006) . For these reasons, more information on drug recovery and stability is required, particularly for those drugs that are likely to be measured in oral fluid.
Sweat
Sweat is a clear, hypotonic solution produced by two types of glands: eccrine and apocrine located in epidermis (Sato et al., 1989) . Water (99%) is its main constituent, as well as high concentrations of sodium and chloride. Low levels of potassium, glucose, lactic and piruvic acids and urea are also present. The sweat from apocrine glands also contains proteins and fatty acids.
Sweat acts physiologically by regulating body temperature, since its evaporation from the skin surface reduces the excess heat. Sweating is increased by nervousness, exercise, stress and nausea and decreased by cold. Sweat excretion is also affected by other factors, such as ambient temperature, relative humidity, body location (in general, sweat glands are distributed over the entire body, except for the lips, nipples and external genital organs), hormonal imbalances, overactive thyroid gland and the sympathetic nervous system, and certain foods and medications.
Between 300 and 700 mL/day of sweat is produced over the whole body, whereas 2-4 L/h may be produced by extensive exercise (Kintz and Samyn, 2000) . Several mechanisms of incorporation of drugs into sweat have been suggested, including passive diffusion from blood into sweat glands and transdermal passage of drugs across the skin. Non-ionized basic drugs diffuse into sweat and become ionized as a result of its lower pH (5.8) as compared with blood (7.4) (Huestis et al., 1999) . Generally, parent drugs are found in sweat, rather than their polar metabolites, which usually predominate in urine (Follador et al., 2004) . As sweat glands are associated with hair, it is thought to be a major contributor to drug appearance in hair, as stated above.
The analysis of drugs in sweat is rarely performed because it is extremely difficult to estimate sweat volume and evaluate drug concentrations, and also to collect adequate quantities. Initially, sweat collection devices consisted of an occlusive bandage formed by one to three layers of filter paper or pieces of cotton, gauze or towel (Kintz and Samyn, 2000) . Heat or chemicals (e.g. pilocarpine) were used to increase sweat production. However, this kind of patch was time-consuming to apply, uncomfortably large, prone to detachment and yielded a small volume of sweat for analysis. In addition, it was found to alter the steady-state pH of the skin, the types of bacteria that colonize the skin and the transport characteristics of the skin, producing skin irritation after approximately 24 h (Huestis et al., 1999) .
To overcome these difficulties, non-occlusive sweat collection devices have been developed, consisting of an adhesive layer on a thin transparent film of surgical dressing to which a rectangular absorbent pad is attached. Non-volatile substances from the environment cannot penetrate the transparent film, which is a semipermeable membrane over the pad that allows oxygen, water and carbon dioxide to pass through the patch, leaving the skin underneath healthy (Kintz and Samyn, 2000) . During wearing of the patch, as sweat saturates the pad and slowly concentrates it, drugs present in sweat are retained, while water evaporates from the patch. Using this non-occlusive design it is not possible to quantitate the concentrations of analytes in sweat, since the whole volume of secreted sweat is not known. Nevertheless, the wear period may be extended (usually a wear period of seven days is used) without skin irritation. Therefore, a cumulative record of drug exposure can be obtained (Huestis et al., 1999) .
In addition, the sweat patches have a unique identification number, which aids with chain of custody and identification. On the other hand, the patch's design makes sample adulteration difficult, because attempts to remove it before the end of the collection period or tamper with it are readily visible to personnel trained to monitor the sweat patch.
Prior to attaching the patch, skin is cleaned with an alcohol wipe, both to remove external contamination from drugs in the environment and to improve patch adherence. Kidwell and Smith (2001) have shown that inappropriate cleansing of the skin prior to patch placement can result in contamination of the patch. Careful preparation of the skin prior to application of a collection device helps to reduce the possibility of bacterial growth and previous skin contamination.
Several papers have been published on sweat testing, including both chromatographic (using mass spectrometry) and immunoassay techniques, particularly for the determination of drugs of abuse. The main detected drugs are opiates, buprenorphine, amphetamines and designer drugs, cocaine and metabolites, and GHB. Prescription drugs, such as benzodiazepines and antipsychotics, have also been detected. A summary of the main detected drugs can be seen on Table 3 .
In general, sweat testing has several advantages over blood and urine, including non-invasive collection, reduced opportunity for sample adulteration, and in some cases, longer detection windows than for plasma or urine. Since the patches are worn for several days, sweat analysis provides cumulative measure of drug exposure, detecting both parent drugs and metabolites. However, as stated above, there is a lack of information concerning dose-response relationships, and analytes are present in low concentrations. In addition, care should be taken during application and removal of the patch, because of the risk of contamination. Another drawback of sweat analysis is related to the impossibility of knowing accurately the volume of sample that was collected. In fact, there is considerably inter-individual variability, due to large variations in sweat production, which makes it difficult to quantitate the amount of sweat that is secreted over a period of time. Therefore, sweat testing is considered a qualitative monitoring method.
Meconium
Meconium is the first faecal matter passed by a neonate and it is identified most commonly by its dark green/ black color and a lack of the odor of regular feces. It is a highly complex matrix consisting of water, mucopolysaccharides, bile salts, bile acids, epithelial cells and other lipids, as well as the residue of swallowed amniotic fluid (Gourley et al., 1990; Ostrea et al., 1994; Kwong and Ryan, 1997; Moore et al., 1998; Chan et al., 2004; Gareri et al., 2006) .
Despite being variably reported to form from within the first trimester to as late as five months of gestation (Kintz and Samyn, 2000) , it is generally accepted that meconium begins to form at approximately 12 weeks of gestation, because it is at this time that fetal swallowing of amniotic fluid begins (Gareri et al., 2006) . The formation of meconium has been evidenced at this stage by the presence of cocaine found in the meconium of early gestational fetuses. Fetal swallowing is thought to be the mechanism by which drugs are concentrated in the meconium; as the fetus releases urine into the amniotic fluid, any excreted compounds and metabolites are then swallowed and ultimately deposited into the meconium Ostrea et al., 2006) . In addition to this mechanism, fetal exposure is a product of maternal consumption, metabolism and elimination, placental transfer and metabolism, and also fetal metabolism (Chan et al., 2004) .
Some authors state that meconium collection from a newborn is more successful than urine collection (Maynard et al., 1991) , which makes meconium the specimen of choice for detecting in utero drug exposure. Furthermore, drug concentrations in meconium generally are higher than in urine because of its accumulation over several months of gestation Bar-Oz et al., 2003; Eyler et al., 2005) . These factors make meconium an optimal matrix for identifying in utero exposure as it is considered a preserved record of the ultimate exposure by the fetus.
Furthermore, it has been suggested that meconium is a more sensitive matrix to analyze for neurotoxicants in the environment when compared with other specimens, because of its wide window of exposure to these compounds. In fact, there is an ongoing study which compares the analysis of various matrices (maternal blood, maternal hair, infant hair, cord blood and meconium) to detect exposure to various pesticides. Preliminary results among 750 mother/infant dyads shows a significantly higher percentage of exposure by meconium analysis (Ostrea et al., 2006) .
One issue that should be taken into account when analyzing meconium is the possibility of urine contamination, which is likely to occur when a neonate has been exposed to a drug near-term and evacuates drug-contained urine into a meconium-soiled diaper, leading to an increase in the sensitivity of meconium screening due to the augmentation of drug levels in the specimen. However, this contamination can interfere with the development of dose-response relationships with regard to the level of drugs present in meconium. Indeed, in this case, the drugs have not been metabolized to the same degree as meconium-deposited drugs, and therefore the expected relationships between drugs and metabolites will be different in meconium.
Meconium collection is easy and non-invasive, and it is achieved by scraping the contents (0.5 g minimum) of the soiled diaper into a specimen collection container, for which contributes its thick and viscous nature. Studies indicate that drugs are stable in this specimen for up to 2 weeks at room temperature and for at least 1 year if frozen (Kintz and Samyn, 2000) .
One major advantage of meconium is a relatively wide window for sample collection. Indeed, meconium contents can provide a history of a fetal swallowing and bile excretion, representing a window of prenatal drug exposure of about 20 weeks prepartum (Moore et al., 1998; Kintz and Samyn, 2000) . It represents, therefore, Abanades et al. (2007 LOD; LOQ 1 ng/patch for all compounds 0.5 ng/patch for heroin, 1 ng/patch for MOR and MAM 10 ng/mL with ELISA 5 ng/mL with GC/MS 25 ng/patch for COC and BE, 50 ng/patch for EME using ELISA, 2.5 ng/patch for COC, 50 ng/patch BE, 100 ng/patch EME using RIA, 1.7-2.5 ng/patch; 7. a repository for many compounds that the fetus has been exposed to during gestation, including a wide variety of licit and illicit drugs, food additives and heavy metals (Bielawski et al., 2005) . After birth, meconium is excreted by the neonate several times a day for the first 1-5 days postpartum. Studies using zinc coproporphyrin (a meconium-specific bile pigment) as a marker have determined that meconium is fully evacuated by 125 h post-natally (Gourley et al., 1990) . Despite these findings, viable analysis appears to be optimal via collection within 72 h, since in the later stages of meconium excretion a matrix of meconium and feces is produced. For instance, analysis of meconium for cocaine and opiates has demonstrated positive results upon third post-natal day sample collection (Ostrea et al., 1998) . In fact, this window of collection covers 99% of term infants, which pass their first formed stool by 48 h. On the other hand, in extremely low birth weight infants, which is of particular interest in the drugexposed neonatal population, median age of first stool is 3 days, with 90% of infants passing their first stool by day 12 (Verna and Dhanireddy, 1993) . For these reasons, the possibility of sample collection beyond 48 h post-natally is a remarkable advantage of this matrix (Ostrea, 2001) . In general, it can be assumed that, in a general neonatal population, meconium can be reliably collected for drug analysis within the first three postnatal days.
As meconium is a very complex matrix, its analysis is often complicated by the presence of large amounts of interferences, resulting in lower sensitivity as compared with the urine, which is a much cleaner specimen.
Meconium analyses usually require a thorough, preliminary clean-up procedure, using liquid-liquid or solid-phase extraction, prior to any analytical assays. This step is very important, especially in GC-MS assays, where sensitivity and specificity are greatly influenced by background noise. Moore et al. (1995) compared several extraction techniques including methanol, acidified water, phosphate buffer with methanol, and glacial acetic acid and diphenylamine in acetone, the latter yielding the best sensitivity. The choice of extraction solvents is based on the physical-chemical characteristics of the drug. For example, Moriya et al. (1994) have used chloroform-isopropanol (3:1) to extract benzoylecgonine, methamphetamine, morphine and phencyclidine. However, for practical reasons, pure or buffered methanol has been the most widely used extraction medium (Kintz and Samyn, 2000) .
Taking into account both matrix complexity and the implications of a positive result, strict criteria for the identification of substances in meconium are needed, since many matrix constituents may elute together with the compounds of interest. Therefore, except for the cases where the molecular ions are detected in the mass spectrum, the presence of breakdown ion masses alone may not be sufficient to identify unambiguously the compounds, unless specific ratios of target ion to qualifiers are also used.
Enzyme multiplied immunoassay test (EMIT) is the most commonly employed screening assay, but fluorescence polarization immunoassay (FPIA), radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) have also been utilized (Moore et al., 1998; Gareri et al., 2006) . All these provide high sensitivity; for example, cut-off values for cocaine and metabolites are less than 50 ng/mg (Ostrea, 2001; Bar-Oz et al., 2003; Moore et al., 1995) .
Meconium is particularly useful in documenting in utero drug exposure (Moore et al., 1998; Gareri et al., 2006; Lozano et al., 2007; Gray and Huestes, 2007) , and a number of papers have been published on the determination of several substances, such as cocaine and metabolites, opiates, cannabinoids, amphetamines, biomarkers of ethanol consumption, pesticides, phtalates, benzodiazepines, tobacco compounds and pollutants and metals, see Table 4 .
Other
As stated above, sensitive and specific analytical techniques have enabled drug testing in other alternative and more complex matrices, with special focus on the early detection of exposure. This is the case for umbilical cord tissue and umbilical cord blood, amniotic fluid and vernix caseosa, which may be used to document in utero drug exposure.
Other alternative specimens, despite being scarcely used routinely in toxicology, do exist, for example pericardial fluid and skeletal muscle, mainly used in post-mortem situations (Garriott, 1991; Moriya and Hashimoto, 1999) .
Umbilical cord tissue and umbilical cord blood.
Umbilical cord tissue is a new alternative specimen, easily and non-invasively collected at birth, and may reflect a long window of drug detection, similarly to meconium. However, using the umbilical cord it is possible to perform the analyses immediately after birth, in contrast to meconium analysis, which is inevitably delayed for up to three days. Several substances have been detected in this specimen, such as amphetamines, opiates, cannabinoids and cocaine (Montgomery et al., 2006) , suggesting that it is more sensitive for detecting amphetamines than, for instance, meconium. Nonetheless, the interpretation of results is difficult, due to the few studies available to date (Gray and Huestis, 2007) . The same goes for umbilical cord blood, which has been used to detect cotinine, antidepressants and cocaine Dempsey et al., 1998; Pichini et al., 2000; Hostetter et al., 2000; Hendrick et al., 2003) . It is expected, however, that the window of detection in cord blood will be quite short, as occurs with maternal blood specimens, being only useful for determining acute exposure to drugs of abuse in the period immediately previous to delivery (Lozano et al., 2007; Gray and Huestis, 2007) .
Amniotic fluid. This sample consists of a filtrate of maternal blood. Drugs can enter amniotic fluid by diffusion across the placenta and from excretion of fetal urine in the latter stages of gestation (Szeto, 1993; Gray and Huestis, 2007) . Amniotic fluid acts as a fetal excretion reservoir, accumulating drugs throughout gestation. The fetus is potentially re-exposed to drugs excreted in urine due to continuous swallowing of amniotic fluid. Another possible route of exposure via amniotic fluid is transdermal diffusion, early in pregnancy when the skin is poorly developed and late in pregnancy when the production of vernix caseosa takes place. The major disadvantage of amniotic fluid is sample collection. In fact, this sample can only be non-invasively collected at birth or as excess specimen from another necessary medical procedure (e.g. amniocentesis). In general, this sample is not collected for monitoring in utero drug exposure alone (Gray and Huestis, 2007; Lozano et al., 2007) . Few papers have been published on drug detection in amniotic fluid Ripple et al., 1992; Jain et al., 1993) .
Vernix caseosa. Vernix caseosa is a thick, white lipid and cell mixture that covers the fetus starting at about 24 weeks of gestational age. This coating prevents direct contact of the forming fetal skin with amniotic fluid. This sample can be easily removed from a newborn's skin with gauze prior to the first bath (Gray and Huestis, 2007) .
The mechanism of drug deposition into vernix caseosa is unknown, but it is possible that the drug is deposited from amniotic fluid. The only paper using this matrix was published by Moore et al. (1996) , in which cocaine and metabolites were detected using solid-phase extraction and chromatographic analysis by GC/MS (Moore et al., 1996) .
Furthermore, the amount of vernix caseosa available for collection is limited, particularly in post-mortem situations, which makes weighing specimens, and therefore quantitative measurements, difficult (Gray and Huestis, 2007) .
CONCLUSIONS AND PERSPECTIVES
The use of alternative specimens is gaining a tremendous importance in the field of toxicology, which is in part due to their non-invasive collection procedures. Analytical equipment is becoming more and more sensitive and specific, which enables both drug detection and quantitation in very low amounts, and analyses where concentrations are expected to be low, such as in hair and oral fluid. In fact, these are the most widely used unconventional specimens, particularly because of their potential use in forensic situations. Nevertheless, documentation of in utero drug exposure has a major appeal nowadays, where the fetus may be exposed during pregnancy to toxic substances, for instance drugs of abuse or pollutants. In these situations, meconium plays an important role, since it is a repository for many compounds to which the fetus has been exposed during gestation. While the main drawbacks are adequately dealt with in cases of hair and oral fluid analyses, further studies are needed with respect to the other matrices, particularly to aid the interpretation of results.
Concerning the complexity of these alternative matrices, it is generally mandatory that the samples are thoroughly cleaned up before chromatographic analysis can be performed, not only to overcome ion suppression/enhancement issues (which can compromise the methods' precision and accuracy), but also to improve the detection limits. In fact, the latter is a very important issue when analyzing these unconventional samples, since in most situations the amount of sample available is small.
The improvements seen in analytical technology have led to the enhancement of the methods' sensitivity and accuracy, providing better scientific understanding and improved test results interpretation. This analytical instrumentation is becoming accessible to most toxicological laboratories worldwide, and therefore it is expected that further applications of these unconventional matrices will appear in the near future.
